Provided by Tiger Fintech (Singapore) Pte. Ltd.

ABBISKO-B

7.300
-0.530-6.77%
Volume:7.11M
Turnover:51.53M
Market Cap:4.94B
PE:151.02
High:7.680
Open:7.680
Low:7.070
Close:7.830
Loading ...

Company Profile

Company Name:
ABBISKO-B
Exchange:
SEHK
Establishment Date:
2016
Employees:
281
Office Location:
Building 3, No. 898,Halei Road,Zhangjiang Hi-Tech Park,Pudong New Area,Shanghai,China
Zip Code:
- -
Fax:
- -
Introduction:
Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).